HOOTONE REMEDIES
Introduces Latest
HBV Treatment
HOO-IMM PLUS-B FDA Approved US-FSM Registered GMP Certified Patented

HOO-IMM PLUS-B, a herbal composite formula ensures
effective action on multiple targets simultaneously anti-HBV,
anti-Hepatocellular Carcinoma (HCC) and Hepatoprotective.
Hero img
Hero img
Hero img
hero shape

ANTI-HBV

HOO-IMM PLUS-B has been extensively clinically studied against HBV on the inhibition of HBsAg secretion and also the inhibition of Hepato carcinoma in HepG2 cell line.
Learn more

ANTI-HEPATOCELLULAR CARCINOMA (HCC)

The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular carcinoma.

Learn more

HEPATOPROTECTIVE

HOO-IMM PLUS-B prevents liver injury from viral hepatitis. HBV individuals receiving HOO-IMM PLUS-B treatment having normalized liver enzyme.

Learn more
shape

ANTI-HBV

icon
The anti-HBV activity of HOO-IMM PLUS-B has been reported by many Ayush clinicians in India and pharmacist from Africa. HOO-IMM PLUS has been extensively clinically studied against HBV on the inhibition of HBsAg secretion and also the inhibition of Hepato carcinoma in HepG2 cell line. Clinically patients receiving Hooimm plus reported Target not detected in HBV Quantitative.

This test is highly recommended in Chronic HBV- World Health Organization (WHO)


Chemopreventive HOO-IMM PLUS-B : Anti-Hepatocellular Carcinoma (HCC)

icon
The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on it suggesting that it inhibits proliferation, induces apoptosis, potentiate attenuate ROS. But the poor systemic absorption of the molecule is major obstacle for its efficacy.
Here we have a unique extraction procedure for said molecule which yields high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption of the molecule.


HEPATOPROTECTIVE

icon
HOO-IMM PLUS-B prevents liver injury from viral hepatitis. HBV individuals receiving HOO-IMM PLUS-B treatment having normalized liver enzyme. The treatment prognosis reports normal level of the routine test of Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST).
AST and SGPT is a blood test that checks for the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.



WHO WE ARE

icon
Hootone Remedies is an Indian pharmaceutical firm registered with FDA and manufacturing according to cGPM Standard Specifications, following the traditional time proven Indigenous Indian ethics of Unani-Ayurvedic system in concurrence with the most modern medical findings, exercising our own innovative techniques for developing drugs for the dreaded diseases like AIDS, Cancer, Leukemia, Hepatitis, Kidney failure, Heart problems & Liver diseases etc confronting the cotemporary world.

Hootone Remedies aims at researching & developing herbal drugs, especially the life saving ones not available in any other system at present and our R&D wing had several landmark achievements to its credit, like formulating the most outstanding anti-retroviral herbal drug HOO-IMM PLUS which recorded 98% inhibition in invitro test.

ANTI HBV DRUG

HOO-IMM PLUS-B an anti-viral treatment for acute and chronic HBV infected patients primarily focus on the viral entry inhibition also inhibit HBV virus in combination with other multi target against HBV which could block re-infection and protect hepatocyte those are healthy liver cells opening a new natural therapeutic options without any means of side effects for HBV infected individuals.

Hepatitis B Virus infection is the major health problem throughout the world affecting more than 350 million people who are carriers of this virus that can cause chronic hepatitis, liver cirrhosis and hepato cellular carcinoma.

HOO-IMM PLUS-B, a herbal composite formula ensures effective action on multiple targets simultaneously anti-HBV, anti-Hepatocellular Carcinoma (HCC) and Hepatoprotective.


5 way actions to combat HBV with the New HOO-IMM PLUS-B :
1) Successive Virologic Response (No viral relapse).
2) Prevents viral induced Hepatocellular Carcinoma.
3) Normalize Liver enzymes (SGPT, SGOT).
4) Reported HBV Not Detected.
5) Anti-HBs Restoration.

Call Now/Whatsapp
(+91) - 9594000093

Clinical Outcome

icon
service

ACTIVE MOLECULES & ACTION. HOO-IMM PLUS-B Polyherbal Formulation Consists Of Number of Active Molecules Of Different Plant Species that Act On Multiple Targets Against HBV.



1) Betulinic Acid, Elagic Acid and Mastic gum prevents the progression of Hepato Carcino genesis. Inhibits proliferation induces apoptosis, potentiate attenuate ROS.
2) Mastic gum and Sesquiterpenoid Glycosides significantly reduces serum HBV DNA (a marker of efficacy) as well as HBeAg (a marker of viral replication) indicating inactivity of the virus and low infectivity.
3) Elagic Acid & Betulinic Acid improves the level of liver enzymes, protects against liver injury due to HBV, significantly increase the anti- oxidant activity protecting acute hepatotoxicity.

service

HBV DNA QUANTITATIVE. Quantification of HBV DNA reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment.

Case 1: Patient dropped Anti-viral drug (TDF) In this present study, HBV patients receiving conventional Anti-viral drug (TDF) had to drop the treatment due to poor compliance (developing jaundice within the interval of 15 days and incidence of elevated SGPT & SGOT level) also virological relapse after cessation of Anti-viral drug (TDF) therapy. The patients discontinued the Anti-viral drug (TDF) therapy due to side effects and went on HOO-IMM PLUS-B therapy. Further the patient followed up every 3 months for monitoring and within the interval of 4-6 months HBV DNA Quantitative level were monitored. After the cessation of Anti-viral drug (TDF) therapy for 21 days, the mean HBV DNA level was 4.7 log IU/ml. With the follow up of HOO-IMM PLUS-B treatment in the first 6 months the mean HBV DNA level was 3.5 log IU/ml and the treatment was continued for 12 months reported Target Not Detected for HBV DNA Quantification.

Case 2: Drug naïve HBV individual receiving HOO-IMM PLUS-B In this present study, the patient never had any medication pertaining to HBV infection, received HOO-IMM PLUS B therapy, they showed good compliance and virological suppressions right after few weeks of treatment. The patients continued the therapy due to the viral decline in the first 4 month of the treatment. Furthermore they followed up for 12 months and they were monitored in the interval of 4 months. The mean HBV DNA level initially found to be 4.5 log IU/ml that has been declined to mean 2.5 log IU/ml in the first 4 months of the treatment to mean 1.46 log IU/ml in the next 4 months of the treatment followed by Target Not Detected in the 12th month monitoring. Moreover, there is a regulated normal liver enzyme throughout the treatment.

service

OTHER ARV'S TREAMTMENT Several Anti-Viral Those Are Currently Available For The Treatment Of HBV Which Includes IFN Alpha and Other ARVs.

Failed ARVs Treatment: Several anti-viral those are currently available for the treatment of HBV which includes IFN alpha and other ARVs. Interferon therapy has limited efficacy, slow acting and frequently causes adverse effect. Undesirable side effects of interferon treatment are found such as fever, malaise, fatigue, depression, hair loss, neutropenia and thrombocytopenia.

On the other hand the side effects of ARVs is no less than Interferon. The common side effects includes fever, pain, diarrhea, vomiting, depressed mood, rashes, insomnia. Moreover, the anti-viral drug and Interferon are expensive. Moreover, if the patient drops the ARVs medication even for 48 hours the HBV viral load elevates to 103.

service

PREVENTING VIRAL INDUCED CARCINOMA.
The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular viral induced Carcinoma.

The HOO-IMM PLUS-B constitute molecules which has been proven a star key molecule in preventing hepatocellular carcinoma. Many research have been done on the molecule suggesting that it inhibits proliferation, induces apoptosis, potentiate attenuate ROS. But the poor systemic absorption of molecule is a major obstacle for its efficacy. Here we have a unique extraction procedure for the said molecule which yields high degree bioavailaibility and along with other herbal extract formulation that improves the gut absorption.

service

ANTI-HBs RESTORATION
HOO-IMM PLUS-B induce functional cure for HBV

Anti-HBs (Hepatitis B Surface antibody) is an antibody that the body naturally produces in response to the exposure against Hepatitis B Virus or vaccination against HBV. When the immune system recognizes the HBV surface antigen, it produces antibodies that bind to the antigen and neutralizes the virus. The antibodies (Anti-HBs) can also prevent future HBV infection.

Different trend of the person do not develop anti-HBs under the influence of Anti-viral drug (TDF). It has been found clinically the patient under the Anti-viral drug (TDF) influences do not develop anti-HBs naturally for even after years of treatment.

Although with the low HBV DNA quant with Anti-viral (TDF) drug, the anti-HBs naturally developing antibodies have not been found against the absence of antigen since anti-HBs is an essential antibody to prevent body from future viral exposure or relapse. In such a case there is a loose end in successive HBV treatment.

On the contrary, HOO-IMM PLUS-B receiving patient develops anti-HBs for the existing viral exposure. The Anti-HBs response induced by HOO-IMM PLUS-B is much more detectable through commercially available anti-HBs test. For any drug-naive patient receiving therapy with HOO-IMM PLUS-B, there will be a noticeable rise in anti-HBs over time.

The patient under Anti-viral drug (TDF) along with HOO-IMM PLUS-B in order to develop anti-HBs the patient has to withdraw Anti-viral drug (TDF) and continue HOO-IMM PLUS-B alone for anti-HBs restoration.

Different bioactive compound of HOO-IMM PLUS-B targets different life activity of the virus apart from immune restoration to bring down the time duration for speedy recovery. It varies from patient to patient since the level of anti-HBs can vary depending on the severity and duration of the infection.

service

Normal Liver Function
Hooimm Plus Prevents Liver Injury From Viral Hepatitis. HBV Individuals Receiving Hooimm Plus Treatment Having Normalized Liver Enzyme.

Hooimm Plus B prevents liver injury from viral hepatitis. HBV individuals receiving Hooimm plus B treatment having normalized liver enzyme. The treatment prognosis reports normal level of the routine test of Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and Aspartate Aminotransferase (AST). AST and SGPT is a blood test that checks for the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.

shape1
shape3

Make an appointment

icon
Enter your detail and get free consultation from our Doctor's on whatsapp

Biomarker or Test Protocol Involved in the Anti-HBV Treatment with HOOIMM plus B:-

icon
1. HBV Serological markers which include HBsAg Elisa.
2. Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) & Aspartate Aminotransferase (AST) or SGOT.
3. HBV DNA Quantification-Viral Load.
4. Anti-HBs Test
Note: Quantification of HBV DNA reflects the viral load which plays a critical role in determining the phase of infection, deciding the treatment and determining the response to anti-viral treatment.


MEDICAL RECORDS

icon

LUCKAS ONESMO (TANZANIA)

July 2018- HBsAg Positive
Nov 2019- HOO-IMM PLUS-B Treatment Started
Feb 2020 - HBsAg (Positive) & HBV DNA Quantitative - 16000 cp/ml
Oct 2020- HBsAg (Positive) & HBV DNA Quantitative - 158 IU/ml
Dec 2020- HBsAg (Positive) & HBV DNA Quantitative - Target Not Detect
March 2021- HBsAg (Negative) & HBV DNA Quantitative - Target Not Detect


KIRAN KOTIYAN (India)

May 2018- HBsAg Positive & HBV DNA Quantitative - 749820 cp/ml
May 2018- HOO-IMM PLUS-B Treatment Started
Dec 2018- HBsAg (Positive) & HBV DNA Quantitative - 23100 cp/ml
June 2019 - HBV DNA Quantitative - Target Not Detected
June 2019 - HBsAg (Negative)

WHAT PEOPLE SAY?

icon
Doctors and Medical experts observation on the patients receiving HOO-IMM PLUS-B and their significant improvement in their anti-HBs development: complete immune restoration against HBV.
avatar1

DR. AGGREY BYAMUKAMA

Uganda
The product works very well against HBV by bringing down the viral load count drastically.
avatar2

PROF DR. MED CHRISTOPHE SIVANZIRE

Congo
We have already reached a 0,00 viral load with Hoo Imm B by one of our patients. A therapeutic success.
avatar3

Dr. ABUBAKAR M'MSAFIRI SWALEHE

Tanzania
The patient had recovered successfully from HBV as reported in his Anti-HBs test after completing 15 months course of treatment
shape1

25

Years of experience

12735

Happy Patients

12

Qualified Doctors

35

Medical Centres

Our Awards & achievements

icon
We have been honoured by the great institutions of the world
shape1
Faq Image

FAQ'S

What is International units per milliliter (IU/ml) and copies per milliliter (copies/ml) with respect to HBV DNA quantification?
The HBV DNA or viral load test can give you a insight into your hepatitis B infection and your health. The HBV DNA test is performed on a blood sample using a Polymerase Chain Reaction (PCR) technique that rapidly generates HBV DNA fragments so they can be measured. Today, viral load is usually measured using international units per milliliter (IU/mL). However, in the past it was measured in copies per milliliter (copies/mL), and in some regions and labs, it is still used.
As per the international units of the WHO HBV DNA standard, there are about 5.6 copies in one international unit, for example, if you need to convert international units to copies into so 893 IU/ml equals about 5,000 copies/ml. Remember to keep copies of your lab information on file so you can track your status. An Excel spreadsheet works great.
Why is it good to use the same lab for HBV monitoring?
The sensitivity of HBV DNA tests may vary with each lab so it’s a good idea to use the same lab for your test. Labs usually measure down to less than 200 IU/mL. Below the threshold, the viral load is considered “undetectable” – something everyone with chronic hepatitis B wants to hear.
What does viral load say about what stage of the virus you are in?
Your viral load also varies over time depending on the “stage” of hepatitis B infection. That is why regular monitoring is so important. Children and adults in the “immune tolerant” stage can have viral loads in the millions or even billions.

It sounds scary, but it’s not unusual. Your viral load can remain very high for decades until your immune system begins attacking the virus. Most children and young adults who test positive for the hepatitis B “e” antigen (HBeAg) generally have high viral loads, though doctors typically don’t treat patients in this stage. Once their immune systems get rid of HBeAg and generate “e” antibodies (HBeAb), their viral loads begin to decline and liver enzymes (ALT/AST) normalize.

Adults with undetectable or low viral loads and no signs of liver damage are in an “inactive” stage. Adults with normal ALT (SGPT) levels, which usually indicate no current liver inflammation, and undetectable or viral loads less than 2,000 IU/mL generally do not require treatment. However, it is important to confirm with your doctor that there is no evidence of advanced liver disease. This phase may be lifelong, decades, or not long at all. That is why monitoring in this inactive phase remains important. People in the “active” stage with elevated viral loads and signs of liver damage need treatment.

These may be people that are HBeAg positive and unable to seroconvert and lose HBeAg and gain the antibody without experiencing significant liver damage. There may be a pattern of SGPT/ALT elevation that cycles up and down over time without mounting an adequate immune response to seroconvert. This can be dangerous, causing liver damage, which is why regular monitoring is key. You want to give your immune system the opportunity to try to mount an immune response and seroconvert but not at the expense of extensive liver damage. That’s why a knowledgeable doctor is so important! Many people in their 40s, 50s or 60s, develop HBeAg-negative hepatitis B, though this may occur in younger individuals as well.

Although individuals may have seroconverted and lost HBeAg (HBeAg negative/HBeAb positive), the virus is able to mutate allowing it to keep replicating, putting these patients at risk of liver damage. They may see the viral load start to creep up along with SGPT/ALT. Eventually they may require treatment with antivirals based on clinical guidelines doctors follow to manage their patients. Once again, monitoring is key!
Why is it important to measure HBV DNA during treatment?
When daily antiviral pills are prescribed, doctors measure your HBV DNA to see if the drug is working to reduce your viral load. Antivirals work by meddling with the viral DNA so the virus cannot reproduce effectively. Doctors measure your viral load to make sure the antiviral is working.
Why is measuring viral load important if you’re pregnant?
Today, all pregnant women are screened for hepatitis B, and experts also want their viral loads to be measured. When pregnant women have high viral loads—exceeding 200,000 IU/mL—medical guidelines recommend antiviral therapy during their third trimester of pregnancy to reduce their risk of infecting their newborns. Babies born to HBV-infected women can become infected even if they are immunized at birth and treated with HBIG (hepatitis B antibodies) if their mothers have high viral loads.

It is important to remember that a viral load test provides you with important information, but it must be considered in relation to your other HBV and liver function tests results to determine if treatment is needed at all, or if you are responding favorably to current treatment. Although an undetectable or low viral load is good news, it does not necessarily guarantee that you have not, or will not experience liver damage. Hepatitis B is a tricky virus. Talk to your liver specialist about all of your test results.
Why HBV treatment is highly recommended?
HBV infection leads to severe diseases, including hepatitis, liver cirrhosis and hepatocellular carcinoma. HBV has also been suggested to be involved in the development of pancreatic cancer.
Approximately 4 crore individuals are infected with HBV, and more than 1.5 lakh people with HBV infection die every year as a result of end-stage liver disease and hepatocellular carcinoma in India. Most of the mortality due to Viral Hepatitis is attributed to Hepatitis B and C, which are also known as silent killers as more than 80% of the infected aren't aware of their infection.

Hepatitis B and C infections can remain asymptomatic for years, even decades, slowly damaging the liver. Fighting hepatitis is difficult because both hepatitis B and C are chronic infections that often remain dormant in the body for years before damaging the liver. Liver cirrhosis and liver cancer are common culminations of these chronic infections.

Most people infected with the virus are not aware about their disease status. Chronic HBV infection accounts for 40-50% of hepatocellular carcinoma (HCC) and 20-30% cases of liver cirrhosis while chronic HCV infection accounts for 12- 32% of HCC and 12-20% of liver cirrhosis in the country.

Subscribe & stay updated

icon
Sign up to our newsletter and be the first to know about latest news,
special offers, events, and discounts.
.
.
(+91) - 9594000093

PROTECT YOURSELF FROM HBV

icon
Preventive measures to be undertaken by the high risk behaviour patients
blog1
blog1
blog1

Brochure -Hootone Remedies



brochure

shape1
shape2

Stay connect with us

icon
You are connected 24x7 with our experts and doctors. Feel free to write to us for any further queries